@ARTICLE{
author={Siefker-Radtke Arlene O,Lugowska Iwona,Tupikowski Krzysztof,Andric Zoran G,Rezazadeh-Kalebasty A,Curigliano Giuseppe,Vaena Daniel A,Vogl FD,Currie Graeme,Abella S,Kelly William Kevin},
year={2019},
title={Clinical activity of vofatamab (V), an FGFR3 selective antibody in combination with pembrolizumab (P) in metastatic urothelial carcinoma (mUC), updated interim analysis of FIERCE-22},
journal={ANNALS OF ONCOLOGY},
volume={30},
number={},
pages={365-365},
document_type={Meeting Abstract},
} 

@ARTICLE{
author={Siefker-Radtke Arlene O,Currie Graeme,Abella Esteban,Vaena Daniel A,Kalebasty Arash Rezazadeh,Curigliano Giuseppe,Tupikowski Krzysztof,Andric Zoran G,Lugowska Iwona,Kelly William Kevin},
year={2019},
title={FIERCE-22: Clinical activity of vofatamab (V) a FGFR3 selective inhibitor in combination with pembrolizumab (P) in WT metastatic urothelial carcinoma, preliminary analysis.},
journal={JOURNAL OF CLINICAL ONCOLOGY},
volume={37},
number={15},
pages={-},
document_type={Meeting Abstract},
}